Literature DB >> 15748963

Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning.

Frédéric Baron1, Marie-Térèse Little, Rainer Storb.   

Abstract

Nonmyeloablative or reduced-intensity conditioning regimens have been used to condition elderly or ill patients with hematological malignancies for allogeneic hematopoietic cell transplantation (HCT). Initial mixed donor/host chimerism (i.e. the coexistence of hematopoietic cells of host and donor origin) has been observed in most patients after such transplants. Here, we describe both factors affecting engraftment kinetics in patients given a nonmyeloablative or a reduced-intensity conditioning, and associations between peripheral blood cell subset chimerism levels and HCT outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 15748963     DOI: 10.1016/j.blre.2004.06.003

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  13 in total

Review 1.  Double cord blood transplants: filling a niche?

Authors:  Richard L Haspel; Karen K Ballen
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 2.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.

Authors:  Brenda M Sandmaier; Stephen Mackinnon; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

Review 3.  G-CSF-primed BM for allogeneic SCT: revisited.

Authors:  I Pessach; I Resnick; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.

Authors:  L Giaccone; M Festuccia; F Zallio; R Sorasio; L Brunello; E Maffini; C Dellacasa; R Passera; G Iovino; S Aydin; M Boccadoro; U Vitolo; N Mordini; M Pini; A Busca; B Bruno
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

5.  Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Authors:  Meagan J Bemer; Linda J Risler; Brian R Phillips; Joanne Wang; Barry E Storer; Brenda M Sandmaier; Haichuan Duan; Brianne S Raccor; Michael J Boeckh; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-09       Impact factor: 5.742

6.  Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Authors:  H Li; D E Mager; B M Sandmaier; D G Maloney; M J Bemer; J S McCune
Journal:  J Clin Pharmacol       Date:  2013-02-04       Impact factor: 3.126

7.  Correlation of infused CD3+CD8+ cells with single-donor dominance after double-unit cord blood transplantation.

Authors:  Filippo Milano; Shelly Heimfeld; Ted Gooley; Jack Jinneman; Ian Nicoud; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-16       Impact factor: 5.742

Review 8.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

9.  Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

Authors:  Cara L McDermott; Brenda M Sandmaier; Barry Storer; Hong Li; Donald E Mager; Michael J Boeckh; Meagan J Bemer; Jennifer Knutson; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-06       Impact factor: 5.742

10.  Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

Authors:  E Gomez; R Duléry; C Langlois; V Coiteux; L Terriou; L Magro; J Gauthier; E de Berranger; A Duhamel; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.